August 1, 2011

A critical eye on Infuse use studies

By: OR Manager

A leading spine journal is casting a critical eye on industry-supported research that has led to widespread use of Medtronic's controversial bone growth product Infuse. The June 2011 issue of Spine Journal carries a strongly worded editorial about the trial designs, reporting bias, and peer review shortfalls that the authors say have promoted the product's widespread use, with "eventual life-threatening complications and deaths."

Welcome to OR Manager, your source of information and insight into the clinical and business management of the surgical suite. This article is only available to OR Manager subscribers. To read this article, and gain access to all OR Manager resources, please log in below:

  Join the OR Manager Community! OR Manager is the trusted source for perioperative leaders, providing critical information, analysis, and best practices for management of the surgical suite. Join as a Premium Subscriber to access all articles online including archives, the digital issue of OR Manager each month, eligibility for CE contact hours, registration discounts on conferences and more. We also offer a complimentary Plus subscription to those who qualify and a complimentary Community subscription.

Explore Subscription Options

Please contact our Customer Service Team if you are unable to log in at [email protected] or 1-888-707-5814.

Join our community

Learn More
Video Spotlight
Live chat by BoldChat